Earlier this week at the 2024 Asembia Specialty Pharmacy Summit in Las Vegas, Managed Healthcare Executive editors spoke with Bill McElnea, vice president of population health at Shields Health Solutions, about specialty pharmacies reducing costs for patients.
Understanding how physician sex contributes to these disparities is crucial as evidence on the impact of physician sex on clinical outcomes remains limited, especially around patient sex.
Tasmina Hydery, Pharm.D., MBA, associate director, digital solutions, Cencora, spoke with MHE editors about the slow uptake of HUMIRA biosimilars despite there being 10 approved options on the market.
These programs aim to enhance the recruitment, training and retention of direct care workers who deliver vital home and community-based services to older adults and individuals with disabilities.
These awards cover research on a variety of crucial health areas including asthma, heart failure, migraine prevention and more.
Five facts based off of findings on women's health.
Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, chatted with MHE editors on the significance of patient acceptance in AI adoption in healthcare, overall and in the dermatology space, stressing trust and transparency.
The executive order was created to acknowledge the challenges faced by families in accessing affordable, high-quality care, mainly due to the gap between costs and what families can afford.
Andel, principal of CommonHealth Solutions LLC, weighed in on potential strategies and challenges for Part D plans in navigating medication formulary limitations during catastrophic coverage phases in this second part of a two-part video series.
According to the co-author of a poster presented at the annual AMCP meeting hosted in New Orleans this week, the interest in the study where the data was found stemmed from the prevalence of PPD in adults, especially women after giving birth.
In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
The proposed rule for the fiscal year (FY) 2025 Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment System introduces strategies to improve the well-being of Medicare beneficiaries, including efforts to tackle social determinants of health, create more robust emergency readiness and enhance maternal healthcare.
Researchers of a study conducted a double-blind intervention that aimed to assess the effectiveness and tolerance of a new approach for vitiligo treatment using meso-microneedling with 5% N-acetylcysteine (NAC) ampoules and topical 4.7% NAC, compared to microneedling alone.
Approved in late September 2022, Relyvrio will no longer be available for new amyotrophic lateral sclerosis (ALS) patients.
Approved in late September 2022, Relyvrio (sodium phenylbutyrate/taurursodiol) will no longer be available for new amyotrophic lateral sclerosis (ALS) patients as of yesterday.
The efforts of the final rule aim to simplify the enrollment process for low-income consumers, provide states with more flexibility in offering routine adult dental services and set guidelines to create access to in-network providers.
As we bring back Managed Healthcare Executive's "Meet the Board" podcast series, MHE welcomes its newest Editorial Advisory Board member Greg Baker, CEO of AffirmedRx.
Though deaths during teen pregnancy and childbirth are uncommon, a study shared in JAMA Network suggests teen pregnancy could indicate adverse experiences during their younger years.
In this second part of a two-part video series, MHE editors spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the cost effectiveness of SGLT2 inhibitors.
The Departments of Health and Human Services (HHS), Labor, and the Treasury, released final rules on short-term, limited-duration insurance (STLDI) and independent, non-coordinated excepted benefits coverage, addressing issues related to the low-quality insurance, or "junk insurance" plans.
Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
With aging populations, osteoporosis rates are set to increase, and researchers are looking for the next innovative drug to help prevent or manage the bone disease as there is currently no drug that completely does so effectively, according to a recent study published in Advanced Science.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Given the role of patient self-management in diabetes care, there has been significant investment in digital diabetes management solutions.
Results from the 2024 State of Patient Access report by the PAN Foundation shared that patients with chronic health conditions, in particular, face barriers to accessing quality care due to costs, coverage gaps and social challenges with healthcare professionals (HCPs).
The latest data showed a 3.9% decrease in national use, dropping from 5.1% of medical claim lines in November to 4.9% in December.
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
